Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.41 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.36 |
| ▸ | NAMPT | P43490 | 2/20 | 0.36 |
| ▸ | BRAF | P15056 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9919054 | 0.78 | L3MBTL1 (0.43) | L3MBTL1IP6K1KDM4EACVR1F2RL3 | |
| SCHEMBL1115838 | 0.76 | L3MBTL1 (0.58) | L3MBTL1IP6K1KDM4EACVR1 | |
| SCHEMBL7268093 | 0.75 | HTR4 (0.39) | ACVR1 | |
| SCHEMBL24569353 | 0.73 | L3MBTL1 (0.48) | L3MBTL1IP6K1KDM4EACVR1F2RL3 | |
| SCHEMBL4252815 | 0.73 | L3MBTL1 (0.59) | L3MBTL1IP6K1KDM4EACVR1ALDH1A1 | |
| SCHEMBL9919058 | 0.73 | L3MBTL1 (0.59) | L3MBTL1IP6K1KDM4EACVR1F2RL3 | |
| SCHEMBL22226939 | 0.73 | L3MBTL1 (0.44) | L3MBTL1IP6K1KDM4EACVR1F2RL3 | |
| SCHEMBL9919057 | 0.73 | F2RL3 (0.51) | L3MBTL1IP6K1KDM4EACVR1F2RL3 | |
| SCHEMBL15680577 | 0.73 | L3MBTL1 (0.50) | L3MBTL1IP6K1KDM4EACVR1ALDH1A1 | |
| SCHEMBL15937428 | 0.71 | L3MBTL1 (0.46) | L3MBTL1IP6K1KDM4EACVR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10624882-B2 | Rho kinase inhibitors | AERIE PHARMACEUTICALS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10624882-B2 | Rho kinase inhibitors | ROCK1, ROCK2, CIT | L3MBTL1 3493/4885IP6K1 347/4885KDM4E 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.